SOPHiA GENETICS (SOPH) Competitors $3.35 -0.11 (-3.18%) Closing price 04:00 PM EasternExtended Trading$3.38 +0.03 (+0.90%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SOPH vs. PHAR, IOVA, TRVI, URGN, PHAT, IMNM, QURE, AVXL, AKBA, and NAGEShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Pharming Group (PHAR), Iovance Biotherapeutics (IOVA), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Immunome (IMNM), uniQure (QURE), Anavex Life Sciences (AVXL), Akebia Therapeutics (AKBA), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Its Competitors Pharming Group Iovance Biotherapeutics Trevi Therapeutics Urogen Pharma Phathom Pharmaceuticals Immunome uniQure Anavex Life Sciences Akebia Therapeutics Niagen Bioscience Pharming Group (NASDAQ:PHAR) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment. Which has more risk & volatility, PHAR or SOPH? Pharming Group has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Does the media favor PHAR or SOPH? In the previous week, Pharming Group had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 3 mentions for Pharming Group and 1 mentions for SOPHiA GENETICS. Pharming Group's average media sentiment score of 0.80 beat SOPHiA GENETICS's score of 0.24 indicating that Pharming Group is being referred to more favorably in the media. Company Overall Sentiment Pharming Group Positive SOPHiA GENETICS Neutral Do institutionals and insiders hold more shares of PHAR or SOPH? 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is PHAR or SOPH more profitable? Pharming Group has a net margin of -2.19% compared to SOPHiA GENETICS's net margin of -40.99%. Pharming Group's return on equity of -3.31% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-2.19% -3.31% -1.78% SOPHiA GENETICS -40.99%-30.69%-17.39% Which has preferable valuation & earnings, PHAR or SOPH? Pharming Group has higher revenue and earnings than SOPHiA GENETICS. Pharming Group is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M3.22-$11.84M-$0.13-107.42SOPHiA GENETICS$65.17M3.47-$62.49M-$0.44-7.61 Do analysts prefer PHAR or SOPH? Pharming Group currently has a consensus target price of $30.00, indicating a potential upside of 114.82%. SOPHiA GENETICS has a consensus target price of $8.00, indicating a potential upside of 138.81%. Given SOPHiA GENETICS's higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00SOPHiA GENETICS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPharming Group beats SOPHiA GENETICS on 9 of the 15 factors compared between the two stocks. Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.82M$2.05B$5.75B$9.77BDividend YieldN/AN/A6.66%4.50%P/E Ratio-7.6137.9882.5826.38Price / Sales3.479.67535.42110.55Price / CashN/A52.0425.7028.92Price / Book2.966.8711.196.58Net Income-$62.49M-$63.67M$3.28B$265.84M7 Day Performance-0.89%0.15%0.15%-0.07%1 Month Performance6.01%10.80%8.34%5.83%1 Year Performance-12.76%31.29%54.21%17.88% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS1.9853 of 5 stars$3.35-3.2%$8.00+138.8%-9.9%$233.82M$65.17M-7.61520Positive NewsShort Interest ↑PHARPharming Group3.0659 of 5 stars$13.23-7.4%$30.00+126.8%+93.0%$906.39M$297.20M-101.77280News CoverageShort Interest ↓Gap UpIOVAIovance Biotherapeutics4.2121 of 5 stars$2.48-2.2%$11.90+380.8%-80.9%$895.58M$164.07M-2.01500Positive NewsTRVITrevi Therapeutics2.5643 of 5 stars$7.32+0.5%$20.11+174.9%+129.7%$890.80MN/A-17.4220News CoveragePositive NewsURGNUrogen Pharma4.5928 of 5 stars$19.10+3.2%$32.00+67.5%+39.8%$885.19M$90.40M-5.76200Positive NewsPHATPhathom Pharmaceuticals2.8873 of 5 stars$12.32+6.5%$17.50+42.0%-26.3%$874.03M$114.04M-2.60110News CoverageIMNMImmunome2.1789 of 5 stars$10.02+1.0%$22.50+124.5%-37.4%$872.54M$12.59M-3.2540Positive NewsQUREuniQure2.424 of 5 stars$15.31-1.6%$37.45+144.7%+179.1%$839.24M$27.12M-3.90500News CoverageAVXLAnavex Life Sciences3.8121 of 5 stars$9.57+1.8%$44.00+360.0%+60.1%$820.68MN/A-16.7640AKBAAkebia Therapeutics3.6705 of 5 stars$3.05+0.5%$6.75+121.7%+102.6%$807.35M$160.18M-17.91430NAGENiagen Bioscience2.0941 of 5 stars$9.96-0.7%$13.42+34.7%N/A$794.31M$99.60M47.43120Analyst UpgradeGap Down Related Companies and Tools Related Companies PHAR Alternatives IOVA Alternatives TRVI Alternatives URGN Alternatives PHAT Alternatives IMNM Alternatives QURE Alternatives AVXL Alternatives AKBA Alternatives NAGE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SOPH) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SOPH Stock Alerts